Overview of Ketorin

What is Ketorin? Defining the Foundational Drug Entity

Ketorin is the trade name for a prescription medicine whose core active ingredient is Ketorolac tromethamine (INN). The substance is fundamentally classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is noted for its powerful pain-relieving efficacy.

Property	Description
Active Ingredient	Ketorolac tromethamine
Forms	Tablets, Solution for Injection, Ophthalmic Solution
Pharmacological Class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose	Provides potent relief from pain, inflammation, and fever
Origin	Synthetic compound (Pyrrolizine carboxylic acid derivative)

What Type of Medicine is Ketorin (Ketorolac)?

Ketorin belongs to the NSAID class and is distinguished by its strong analgesic and anti-inflammatory characteristics, often used where a high level of pain management is required. Unlike many common NSAIDs, Ketorolac is a synthetic compound, chemically identified as a pyrrolizine carboxylic acid derivative. It is recognized as a potent analgesic. The availability of Ketorolac in various dosage forms, including tablets for oral intake, a sterile solution for injection for systemic administration, and an ophthalmic solution for topical use, demonstrates its versatility in allowing administration via both systemic and topical routes. Ketorolac is clinically recognized for its use in short-term pain management, distinguishing it from agents intended for chronic conditions.

General Purpose and High-Level Action

The general purpose of Ketorolac is to provide rapid and effective interruption of the pain and inflammation cycle, serving as a powerful non-opioid analgesic. Its high-level mechanism involves the inhibition of the cyclooxygenase (COX) enzyme system, which blocks the production of prostaglandins—chemical messengers in the body that directly cause pain and swelling. This action is the core reason the drug is chosen for general therapeutic use, such as providing comfort to adult patients experiencing acute, moderate to severe pain. This means that the medication works by stopping the chemicals that cause your body to feel discomfort and swell. Its primary benefit is to diminish moderate to severe pain, reduce associated inflammation, and achieve an antipyretic effect where fever is present.

Regulatory References

NIH MedlinePlus Drug Information on Ketorolac

What side effects are possible with Ketorin?

Possible Side Effects and Safety Information

The safety profile of Ketorolac tromethamine (Ketorin), a Nonsteroidal Anti-Inflammatory Drug (NSAID), is structured by regulatory agencies around the nature, frequency, and severity of potential adverse reactions, with an emphasis on systemic risk. The medicine’s use is confined to short-term therapy due to documented risks associated with prolonged exposure.

Official Adverse Reaction Classifications

Adverse reactions are grouped according to the physiological systems affected, including Gastrointestinal Disorders, Renal and Urinary Disorders, and Nervous System Disorders. Common adverse reactions, frequently reported in official labeling, include headache, dizziness, nausea, diarrhea, dyspepsia, and edema.

Serious Adverse Reactions and Systemic Risks

Serious adverse events are explicitly documented in regulatory sources and represent the most critical safety considerations. These include a risk of serious Gastrointestinal Adverse Events, such as ulceration, bleeding, or perforation, which can occur without warning symptoms. Furthermore, the use of Ketorolac is associated with an increased risk of Cardiovascular Thrombotic Events, including myocardial infarction (heart attack) and stroke.

Serious Renal Adverse Events, such as acute renal failure, are also documented risks, particularly in vulnerable patients.

Safety Constraints and Special Populations

Official labeling mandates specific safety constraints. The drug is contraindicated in patients with a history of active peptic ulcer disease, recent gastrointestinal bleeding, or advanced renal impairment. Older adults are officially noted to be at a greater risk for serious gastrointestinal adverse events. Regulatory documents stipulate that the risk of serious adverse events increases with the duration of use, thereby limiting the total course of therapy.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Ketorolac tromethamine defines the overdose profile primarily by its effects on the gastrointestinal (GI) and central nervous systems (CNS).

Documented Manifestations

Symptoms following an acute overdose are typically limited to reversible effects, including lethargy, drowsiness, nausea, vomiting, epigastric pain, and abdominal pain. Single overdoses have also been associated with specific physiological findings, such as renal dysfunction, peptic ulcers, and erosive gastritis.

Serious Outcomes and Required Emergency Action

While most effects are reversible, regulatory sources document the potential for rare, severe outcomes, including acute renal failure, hypertension, respiratory depression, and coma. Life-threatening events such as GI bleeding or perforation are also noted as potential complications.

Urgent medical attention is required for any known or suspected overdose due to the potential for these severe and potentially fatal outcomes.

Management and Antidote Information

There are no specific antidotes documented for Ketorolac overdose. Management is based on providing symptomatic and supportive care. Healthcare professionals may consider decontamination procedures, such as administering activated charcoal, following a large oral overdose within a specified timeframe. Procedural interventions like hemodialysis are noted as having limited utility due to the drug’s high protein binding.

Population Note: Regulatory labeling indicates that elderly patients and individuals with existing impaired renal function are at increased risk for serious complications in an overdose setting.

Therapeutic Uses of Ketorin

What Ketorin Treats: Main Uses and Benefits

Ketorin (Ketorolac) generally provides supportive relief for managing symptoms related to physical discomfort, offering symptomatic assistance in specific clinical settings where symptoms related to inflammatory or irritative states are acute. The medication is primarily used for short-term management of moderately severe acute pain.

It is considered relevant in contexts involving heightened systemic burden, such as managing postoperative pain, treating acute episodes like renal colic (kidney stone pain), or severe migraine headache attacks. The medication may assist with managing the intensity of pain and supports patients during difficult episodes by easing distress. In its localized form, it is applied in addressing inflammation and pain following specific surgical procedures, such as cataract surgery.

“The use of this medication may assist with managing symptoms related to physical discomfort, which is relevant in contexts marked by increased discomfort or tension.”

This approach contributes to easing the overall symptom load during periods of heightened symptoms and supports patients during episodes of heightened discomfort, as it is used for managing symptom clusters that may become intense or disruptive.

Quick Fact: Relief for Acute Discomfort
Primary Therapeutic Goal	Short-term management of pain intensity.
Associated Symptoms	Pain, inflammation, and fever.
Key Patient Benefit	Assists with maintaining functional stability.

Regulatory References

Label: KETOROLAC TROMETHAMINE tablet - DailyMed

Eligibility and Restrictions for Use

The eligibility for using Ketorin (Ketorolac) is strictly governed by patient characteristics and pre-existing conditions as defined in official regulatory documents. Use is generally indicated for adults (typically ge 17 years) for short-term pain management. Safety and efficacy have not been established in most pediatric patients.

Populations for Whom Use is Contraindicated

The medicine is CONTRAINDICATED in patients with:

Condition/Status	Regulatory Classification
Advanced renal impairment or volume depletion risk	Absolute Contraindication
Active peptic ulcer disease or recent GI bleeding/perforation	Absolute Contraindication
Hemorrhagic diathesis or high bleeding risk (e.g., cerebrovascular bleeding)	Absolute Contraindication
Aspirin or other NSAID hypersensitivity	Absolute Contraindication
Labor and delivery or lactation (nursing mothers)	Absolute Contraindication
Peri-operative pain in the setting of CABG surgery	Absolute Contraindication

Eligibility-Related Restrictions

Use requires extreme caution and often mandates a reduced maximum daily dose for geriatric patients (ge 65 years), patients weighing less than 50 kg, and patients with mild-to-moderate renal impairment. Additionally, use is avoided from 30 weeks gestation onward in pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ketorin (ketoprofen) is a nonsteroidal anti-inflammatory drug (NSAID) and its use with certain medicines, products, or substances can increase the risk of serious adverse effects such as bleeding, kidney impairment, or reduced efficacy of the co-administered drug.

Key interaction groups include:

Interacting Product Category	Potential Effect	Interaction Basis (Official)
Anticoagulants/Anti-platelets (e.g., warfarin, aspirin, clopidogrel)	Increased risk of severe bleeding and gastrointestinal ulceration.	Additive effects on bleeding risk.
Other NSAIDs (e.g., ibuprofen, naproxen, ketorolac)	Increased risk of side effects, including gastrointestinal bleeding and ulceration.	Additive toxicity; co-administration is generally not recommended.
ACE Inhibitors/ARBs/Diuretics	Risk of reduced antihypertensive/diuretic effects; increased risk of kidney impairment (nephrotoxicity).	Affects renal function, especially in older or volume-depleted patients.
Lithium, Methotrexate	Risk of increased serum levels and toxicity of the co-administered drug.	Decreased renal clearance.
Corticosteroids (e.g., prednisone)	Increased risk of gastrointestinal ulceration and bleeding.	Additive gastrointestinal toxicity.

Additionally, alcohol consumption should be limited due to an increased risk of gastrointestinal bleeding. For topical ketoprofen formulations, a specific risk exists for photoallergic reactions when the application area is exposed to sunlight or when used concurrently with products containing the sunscreen ingredient octocrylene.

Mechanism of Action

Direct Modulation of Key Receptor and Enzyme Systems

This primary mechanistic domain involves Ketorin's binding to specific enzymatic or receptor targets within the body, which are core regulators of biochemical activity. By initiating or suppressing signaling at this initial molecular step, the drug modulates the activity of specific targets, altering the transmission of excessive signaling, thus shaping the fundamental biological response.

Targeted Interference in Signal Transduction Cascades

Following target binding, Ketorin acts within well-characterized signal transduction cascades. This mechanism affects the flow of information along the pathway, particularly in contexts involving heightened pathway activation. Modifying these intermediate steps alters the rate or intensity of signal transduction, influencing downstream effects of dysregulated mediators and affecting signal dynamics within specific physiological responses.

Influence on Central and Peripheral Regulatory Feedback

Ketorin's mechanism affects the adjustment of activity within defined central or peripheral pathways where regulatory feedback mechanisms are engaged. By applying targeted pathway interference, the drug influences feedback mechanisms, modifying the behavior of specific physiological responses and resulting in altered central and peripheral pathway activity.

Dosage and Administration Information

Ketorin (Ketorolac tromethamine) is administered according to a strict, sequential protocol to govern its short-term use. Systemic therapy is primarily initiated through the Intramuscular (IM) or Intravenous (IV) injection route in a professional setting. The oral tablet formulation is specifically indicated only as continuation therapy following this initial parenteral course and should not be used as an initial starting dose.

Official Dosing and Duration

The most fundamental constraint is that the total combined duration of use—including all doses given via injection and oral tablet—must not exceed 5 days in adults. Dosing frequency for systemic use is typically 30 mg every 6 hours, while oral continuation is 10 mg every 4 to 6 hours as needed.

Regimen Type	Standard Adult Dose	Maximum Daily Dose
Multiple-Dose IV/IM	30 mg every 6 hours	120 mg
Oral Continuation	10 mg every 4 to 6 hours	40 mg

Population Adjustments and Procedure

Dose reduction is required for several patient groups. The maximum recommended daily IV/IM dose is reduced to 60 mg per day for older adults (65 years and over), patients weighing less than 50 kg, and those with impaired kidney function. Procedural instructions also require that an IV bolus injection must be administered over no less than 15 seconds, and the injection should not be mixed with certain solutions (e.g., morphine or meperidine) due to potential physical incompatibilities.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ketorin

This overview focuses exclusively on the findings from official clinical evaluations, such as randomized controlled trials and regulatory summaries, to describe the existing body of research for Ketorin (Ketorolac). This information describes group patterns observed in studies, not to offer clinical advice or personal treatment recommendations.

Evidence for Managing Acute, Moderately Severe Pain

Research examined the use of Ketorolac during episodes where symptoms become more noticeable, specifically focusing on measurements of short-term pain intensity. The research base for this use includes Randomized Controlled Trials (RCTs) and Systematic Reviews that included adult patients reporting acute, moderate to severe physical discomfort. Studies monitored patient-reported outcomes describing perceived discomfort. Research reports indicate patterns where the measured pain scores differed when compared to those observed in participants receiving a placebo. Studies explored whether the use of Ketorolac was associated with a lower reported amount of supplemental pain relievers during the acute period.

Evidence in Specific Acute Pain Settings

Dedicated clinical trials have explored the role of Ketorolac in conditions characterized by fluctuating or episodic manifestations.

Research Summary for Postoperative Pain

Ketorolac was studied for managing pain following a variety of surgical procedures in adults. Studies monitored patient-reported outcomes describing perceived discomfort and examined the total consumption of opioid medication. Trials reported observations where the consumption of opioids was lower in patients receiving Ketorolac compared to those receiving placebo. Findings also described pain measurement scores that, in some cases, were similar to those observed for other nonsteroidal anti-inflammatory drugs (NSAIDs).

Research Summary for Renal Colic and Migraine

Ketorolac was evaluated in studies focusing on acute episodes such as renal colic (kidney stone pain) and severe migraine headache attacks. Research in these contexts focused on very short-term changes. For acute renal colic, studies primarily examined injectable forms of the drug and reported measurements of pain score reduction that appeared similar to those observed for opioid comparators within the first hour of administration.

Areas of Evidence Uncertainty and Research Gaps

Scientific summaries indicate the primary gaps involve the lack of long-term outcomes beyond the initial five-day treatment period. Follow-up durations were limited across the vast majority of studies, meaning that long-term effects are not fully established. Additionally, the available data for pediatric (child) populations remain insufficient compared to the adult evidence base, and findings for certain age ranges are uncertain.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ketorin (FAQ)

Q: How quickly should I expect Ketorin to start working after I take it?

A: According to official product information, when Ketorin is given by injection (IV or IM), the pain-relieving effects typically begin within 30 minutes of administration.

The maximum pain relief effect is usually felt about 1 to 2 hours after receiving the dose. Official product information notes that oral absorption is also generally rapid.

Q: Can Ketorin be taken on an empty stomach, or is food necessary?

A: Regulatory patient information often suggests that the oral tablets should be taken with food (such as a meal or a snack) or possibly with an antacid. This recommendation is often given to help minimize stomach upset, as the medicine is known to cause gastrointestinal irritation.

Q: Is it normal to feel a bit dizzy after taking Ketorin?

A: Regulatory documents list dizziness as a frequently reported adverse reaction. Like other medicines that can affect the central nervous system, other effects such as headache or drowsiness may also be noted.

Q: Are there any concerns about taking Ketorin if I have a history of kidney stones?

A: Official warnings state that Ketorin is not suitable for use in patients with advanced renal (kidney) impairment. Official labeling states that caution is required if there is any history of issues affecting kidney function, even though the medication is studied for treating the acute pain of renal colic (kidney stones).

Q: Can Ketorin be taken with antacids to help reduce stomach irritation?

A: Patient information derived from regulatory sources often suggests that oral tablets can be taken with an antacid.

Taking it with an antacid is often suggested to potentially help minimize irritation of the digestive tract.

Q: How long does the pain relief from one dose of Ketorin typically last?

A: Based on regulatory pharmacological data, the duration of the analgesic effect for a single systemic dose (given by injection) is generally reported to be 4 to 6 hours.

Q: Can people with high blood pressure safely use Ketorin?

A: Official warnings indicate that Ketorin, like other NSAIDs, may cause the new onset or worsening of existing high blood pressure (hypertension). Caution is advised for patients with existing high blood pressure.

Due to the risk of fluid retention, use in patients with conditions like heart failure requires careful consideration.

Q: What happens if I accidentally take a dose of Ketorin too close to the last one?

A: Regulatory guidance generally advises patients to not take a double dose when a dose is missed. If the next dose is almost due, the missed dose should be skipped, and the regular schedule resumed.

Using the medicine more frequently than prescribed increases the chance of unwanted side effects.

Q: Does Ketorin affect sleep patterns or cause insomnia?

A: The official product information lists both insomnia (difficulty sleeping) and drowsiness among the possible central nervous system side effects reported by patients.

Q: Is there a generic version of Ketorin available that works the same way?

A: Yes, the active ingredient in Ketorin, ketorolac tromethamine, is available in generic versions. These are approved by regulatory agencies as therapeutically equivalent to the branded product, meaning they are expected to work in the same way.

Q: Can children or teenagers take Ketorin for minor injuries or fevers?

A: Systemic ketorolac is not indicated for use in pediatric patients.

Its safety and efficacy have not been established in these younger age groups, and the medication is not intended for minor painful conditions.

Q: Is Ketorin available without a prescription in some countries?

A: In the United States, systemic forms of the active ingredient are designated as prescription-only medications. This is due to the potential for serious side effects that require professional monitoring and short-term use limits.

Q: Is it possible for Ketorin to affect the results of certain medical tests?

A: Official warnings note that the medicine can increase bleeding time by interfering with the function of platelets.

This interference with platelet function can impact the results of certain blood tests related to clotting.

Q: How should Ketorin be stored, and does it expire?

A: The product label specifies that oral tablets must be stored at controlled room temperature and kept in a tight, light-resistant container. All forms of the medication have an expiration date.

As with all medications, it must be stored out of the sight and reach of children.

Q: Why do some people experience swelling or fluid retention while taking Ketorin?

A: Swelling, or edema, is a common side effect reported in official documents.

Official product information attributes this effect to the drug's mechanism causing sodium and water retention in the body.

Q: Does Ketorin have a significant impact on liver function?

A: Regulatory warnings indicate that NSAIDs can cause elevations in liver function tests.

If symptoms of liver toxicity (such as jaundice) appear, official guidance states that the use of the medication should be discontinued.

Q: What are the most common reasons patients stop taking Ketorin?

A: Regulatory documents impose a strict limit of 5 days of total use for the medicine.

This is because the risk of serious adverse events (such as gastrointestinal bleeding or cardiovascular issues) increases significantly with prolonged duration.

Q: Does the effectiveness of Ketorin change with a person's weight or age?

A: Yes, official dosing information requires dose adjustments for older patients (65 years or above) and for patients weighing less than 50 kg.

These adjustments are required to ensure the correct balance between effectiveness and minimizing the risk of adverse effects in these specific groups.

Q: Why do people sometimes say Ketorin is stronger than over-the-counter pain relievers?

A: The drug is officially indicated for the management of moderately severe acute pain.

This classification indicates the drug is intended for a level of pain relief often associated with more severe, acute pain, unlike medications typically indicated for non-prescription use.

Q: Is Ketorin only available as a pill, or are there other forms (e.g., injection, cream)?

A: The active ingredient (ketorolac tromethamine) is supplied in multiple forms for different uses.

These include oral tablets, a solution for injection (IV or IM), and an ophthalmic solution (eye drops).

Q: How does Ketorin specifically target pain signals in the body?

A: Ketorolac works by blocking the activity of key enzymes called Cyclooxygenase (COX) enzymes.

This action significantly reduces the synthesis of prostaglandins, which are the chemical messengers responsible for mediating pain signaling, inflammation, and fever.

Q: Do clinical trials show Ketorin is more effective than placebo for acute pain?

A: Official clinical trial summaries confirm that the drug provided significantly greater pain relief compared to placebo (an inactive substance) for measurements of acute, moderately severe pain.

How should Ketorin be stored and disposed of?

Storage and Handling Requirements

Ketorolac Tromethamine storage conditions are defined by regulatory documents based on the specific formulation. Tablets must be stored at controlled room temperature, typically 15 C to 30 C. The injection solution requires storage at 20 C to 25 C and must be protected from light; it is prohibited to freeze the injection. Tablets must be kept in a tight, light-resistant container.

Child Safety and Disposal

All forms of this medication must be stored out of the sight and reach of children. The nasal spray formulation must be discarded within 24 hours after taking the first dose. Unused or expired product and containers must be disposed of in accordance with all local and national requirements; regulators specify that disposal should not occur via wastewater or household garbage.

Ketorin